Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Eagle Capital Growth Fund Inc. (GRF)

8.17   0.02 (0.25%) 02-14 14:50
Open: 8.23 Pre. Close: 8.15
High: 8.23 Low: 8.155
Volume: 3,032 Market Cap: 32M
Eagle Capital Growth Fund Inc is a diversified closed-end investment company.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 8.24 - 8.271 8.271 - 8.295
Low: 8.086 - 8.125 8.125 - 8.157
Close: 8.112 - 8.172 8.172 - 8.22

Technical analysis

as of: 2020-02-14 4:29:16 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 9.61     One year: 11.23
Support: Support1: 7.85    Support2: 7.61
Resistance: Resistance1: 8.23    Resistance2: 9.61
Pivot: 7.91
Moving Average: MA(5): 8.07     MA(20): 7.88
MA(100): 7.88     MA(250): 7.81
MACD: MACD(12,26): 0.08     Signal(9): 0.05
Stochastic oscillator: %K(14,3): 82.54     %D(3): 82.22
RSI: RSI(14): 67.23
52-week: High: 8.45  Low: 7.10  Change(%): 7.9
Average Vol(K): 3-Month: 629  10-Days: 654

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
GRF has closed below upper band by 1.2%. Bollinger Bands are 14.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

2019-12-12
Grifols launches XEMBIFY® (immune globulin subcutaneous human-klhw) 20%, a new Primary Immunodeficiency treatment
BARCELONA, Dec. 12, 2019 /PRNewswire/ -- Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced the launch of its latest immunoglobulin (IG) innovation, XEMBIFY® (immune globulin subcutaneous human-klhw), the company's first 20%…

2019-12-02
Global Blood Grouping Reagents Market 2020-2024 | Evolving Opportunities with DIAGAST and Grifols SA | Technavio
LONDON--(BUSINESS WIRE)-- #Biotechnology--Global blood grouping reagents market is poised to grow by USD 443.28 million during 2020-2024 at a CAGR of over 10% during the forecast period.

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE American
Sector:  Financial Services
Industry:  Asset Management
Shares Out. (M) 3.89
Shares Float (M)
% Held by Insiders 13.79
% Held by Institutions 6.46
Shares Short (K) 2
Shares Short P. Month (K)

Stock Financials

EPS 1.160
Book Value (p.s.) 9.440
PEG Ratio
Profit Margin 599.60
Operating Margin 41.23
Return on Assets (ttm) 0.6
Return on Equity (ttm) 13.0
Qtrly Rev. Growth -14.5
Gross Profit (p.s.) 0.209
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth
Operating Cash Flow (M)
Levered Free Cash Flow (M)

Stock Valuations

P/E 7.04
P/E Growth Ratio
P/BV 0.87
P/S 43.00
P/CF

Dividends & Splits

Dividend 0.530
Dividend Yield 0.06
Dividend Pay Date 2018-12-27
Ex-Dividend Date 2019-11-20
Forward Dividend 0.560
Last Split Date
Last Split Ratio 1.1
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2019 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.